Tarveda to Present at North American Neuroendocrine Tumor Society (NANETS) Symposium
- Preclinical data demonstrates PEN-221 is a potent and selective Pentarin that causes complete and sustained tumor regressions in SSTR2 positive cancer models –
WATERTOWN, MA–September 29, 2016 —Tarveda Therapeutics, Inc. a biopharmaceutical company discovering and developing Pentarins™ as a new class of targeted anti-cancer medicines, today announced that the company will present at the 2016 North American Neuroendocrine Tumor Society (NANETS) Symposium, September 30 – October 1, at the Jackson Lake Lodge, Grand Teton National Park, in Jackson, Wyoming.
Dr. Richard Wooster, President, Research & Development and Chief Scientific Officer, will present a poster at the meeting titled “The Pentarin Miniaturized Drug Conjugate PEN-221 Targets the Potent Cytotoxic DM1 to Somatostatin Receptor 2 Expressing Cancers”. The poster will be on display beginning Friday, September 30, at 12:30 p.m. MST.
PEN-221 is Tarveda’s lead Pentarin that consists of a peptide ligand that is highly selective for the somatostatin receptor SSTR2. This somatostatin receptor is overexpressed on the surface of cancer cells in a variety of neuroendocrine cancers, including small cell lung cancer. The targeting ligand is chemically linked in a unique and optimized fashion to the potent cell-killing payload DM1. In preclinical studies, PEN-221 has demonstrated the desired pharmacokinetics and deep tumor penetration with complete tumor regressions in multiple, hard to treat xenograft cancer models and has demonstrated superiority to the clinical standard of care. Tarveda is advancing PEN-221 to enter the clinic in 2016.
Pentarins are miniaturized drug conjugates that represent a novel approach for the application of drug conjugates to the treatment of cancer. Tarveda applies its proprietary suite of technologies to create Pentarins comprised of a targeting ligand conjugated to a potent cell-killing agent through a chemical linker. Pentarins are designed to overcome the biological barriers that limit therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct yet synergistic anticancer capabilities: the small size of Pentarins allows for effective penetration and distribution into the tumor tissue, the ligand’s targeting ability allows for specific binding to tumor cells, and the cell-killing payload is released inside the cancer cells for efficacy.
About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc., is a biopharmaceutical company discovering and developing Pentarins™ as a new class of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniaturized biologic drug conjugate that targets the somatostatin receptor for treatment of patients with neuroendocrine cancers including small-cell lung cancer. Tarveda is also advancing its HSP90 drug conjugate platform with lead PEN-866, which is a drug conjugate that comprises an HSP90 ligand conjugated to SN-38, the highly-potent, active metabolite of irinotecan. Tarveda’s strategy includes developing its own proprietary Pentarins as well as applying the Pentarin platform to enhance the effectiveness of the targeting moieties and novel payloads of pharmaceutical collaborators. Tarveda has attracted top-tier investors including Novo A/S, New Enterprise Associates, Flagship Ventures, NanoDimension, and Eminent Venture Capital. www.tarveda.com